Drug
Sialic Acid
Sialic Acid: highest development phase Phase 2, developed by Ultragenyx Pharmaceutical. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sialic Acid Extended Release (SA-ER) NCT01517880 | Phase 2 | GNE Myopathy |
| Sialic Acid Extended Release (SA-ER) Tablets NCT01359319 | Phase 1 | Hereditary Inclusion Body Myopathy (HIBM) |
Latest
No recent events.
Follow Sialic Acid on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.